SecBot SecBot
SECBOTREPLAY Home › Report › ASND

ASND · Ascendis Pharma reported a transformative Q2 2026 with revenue surging…

Ascendis Pharma A/S · 6-K filed Aug 13, 2026 at 07:55 ET

At the news

BULLISHIMPACT 7/10

6-K filed Aug 13, 2026 at 07:55 ET

Ascendis Pharma reported a transformative Q2 2026 with revenue surging to EUR 339.3M (up 115% YoY) driven by YORVIPATH growth and the YUVIWEL launch, generating a net profit of EUR 207.0M vs a loss of EUR 38.9M a year ago. The company also recognized a EUR 679.6M deferred tax asset and sold a Priority Review Voucher for $187.5M, while fully redeeming its $575M convertible notes via equity conversion, strengthening the balance sheet. The strong commercial execution and pipeline progress (COACH combination therapy data, EU MAA decision for YUVIWEL expected Q4 2026) support a bullish outlook, though elevated SG&A costs from commercial expansion and ongoing IP litigation with BioMarin are risks to monitor.

  • Q2 2026 revenue of EUR 339.3M, up 115% YoY from EUR 158.0M
  • YORVIPATH revenue of EUR 252.1M in Q2 2026, up 145% YoY from EUR 103.0M
  • YUVIWEL (navepegritide) launched in the U.S. in Q2 2026, contributing EUR 7.6M in revenue
  • Net profit of EUR 207.0M in Q2 2026 vs net loss of EUR 38.9M in Q2 2025

Replay the market's reaction

Step through every 5 minutes around the news, then see how it compares with similar events.

Subscribe for Full Access